Sucampo announces Japanese funding for unoprostone isopropyl development Sucampo Pharmaceuticals announced that the Japan Science and Technology Agency has adopted unoprostone isopropyl ophthalmic solution .15% in the Adaptable and Seamless Technology Transfer Program. As part of this program, R-Tech Ueno, Sucampo’s development partner, has signed an agreement for unoprostone isopropyl with the JST in which the Japanese government shall provide the majority of funding for Phase 3 clinical development costs for unoprostone isopropyl for retinitis pigmentosa. Sucampo is co-developing unoprostone isopropyl with R-Tech Ueno and may file for FDA approval of the product for retinitis pigmentosa in the future assuming the successful trials.
News For SCMP From The Last 14 Days
Check below for free stories on SCMP the last two weeks.
Sucampo to hold a pharmaceutical update meeting Pharmaceutical update to discuss the recent opioid-inducted constipation (OIC) indication approval for Sucampo's Amitiza is being held in Orlando, Florida on May 20 at 9 am. Webcast Link